Last reviewed 2026-04-23 · How we verify

Irbesartan/Amlodipine low

This combination drug lowers blood pressure by blocking angiotensin II receptors (irbesartan) and calcium channels (amlodipine) to reduce vascular resistance and improve blood flow.

This combination drug lowers blood pressure by blocking angiotensin II receptors (irbesartan) and calcium channels (amlodipine) to reduce vascular resistance and improve blood flow. Used for Hypertension.

At a glance

Mechanism of action

Irbesartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from constricting blood vessels, while amlodipine is a dihydropyridine calcium channel blocker that relaxes vascular smooth muscle by blocking calcium influx. Together, these complementary mechanisms provide synergistic antihypertensive effects with improved efficacy compared to monotherapy.

Approved indications

• Hypertension

Common side effects

• Peripheral edema
• Dizziness
• Fatigue
• Headache
• Hyperkalemia

Key clinical trials

• Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients (PHASE3)
• Low-dose Quadruple Combination Therapy in Patients With Hypertension (PHASE4)
• Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Irbesartan/Amlodipine low CI brief — competitive landscape report
• Irbesartan/Amlodipine low updates RSS · CI watch RSS
• Handok Inc. portfolio CI